Psyence BioMed Announces Approval for Use of PsyLabs Psilocybin Product in Phase IIb Clinical Trial
NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq:…
PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares
June 18, 2025 17:36 ET Â | Source: Psyence Group Inc. TORONTO, June…